Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)

INTRODUCTION: Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jim, Brown, Sarah, Serra, Maria, Shuttleworth, Pam, Bownes, Peter, Thompson, Christopher, Reed, Rachel, Reeves, Kimberley, Dubec, Michael, McHugh, Damien, Eccles, Cynthia, Chuter, Robert, Tsang, Yat Man, Taylor, N Jane, West, Catharine, Buckley, David, Scarsbrook, Andrew, Choudhury, Ananya, Hoskin, Peter, Henry, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644357/
https://www.ncbi.nlm.nih.gov/pubmed/36351720
http://dx.doi.org/10.1136/bmjopen-2022-068580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644357/
https://www.ncbi.nlm.nih.gov/pubmed/36351720
http://dx.doi.org/10.1136/bmjopen-2022-068580

Ejemplares similares